CELC: Celcuity Company Total Revenue

Celcuity Inc. is implementing a unique live-cell analysis method for precision therapy selection. The company's sales history clearly demonstrates cash flow dynamics, while the 0.00 metric confirms the current level. The environmental development vector is based on laboratory energy efficiency, and the robotization of cell testing processes is systematically optimizing routine research.

Celcuity Inc. (CELC) Revenue and Sales Volume: for the period 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Celcuity (CELC)

- stock quotes and analyst forecast:

Price Chart Celcuity Therapeutics|CELC - Consensus Target

- market capitalization information:

Market Value Celcuity Inc.|CELC - Total Company Value

- book value of equity indicators:

Net Assets per Share Celcuity|CELC - Book Capitalization|Market Capitalization to Book Value celcuity.com|CELC - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

CELC - Net Income|Projected Future Earnings Celcuity Inc.|CELC - P/E Multiple|Market Cap to Projected Earnings celcuity.com|CELC - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Celcuity Inc.|CELC - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Celcuity|CELC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months celcuity.com|CELC - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Celcuity Inc.

- company sales and revenue statistics:

CELC - Company Revenue|Company Revenue Forecast Celcuity Therapeutics|CELC - P/S Multiple|Forward Price-to-Revenue Multiple Celcuity Inc.

Summary company analysis:CELC (Celcuity Therapeutics)

This indicator tracks daily revenue from core commercial activities, allowing for an assessment of real demand dynamics and operational efficiency. An analysis of Celcuity Inc. absolute sales reveals a resilient cash flow, which is driven by the integration of diagnostic systems into clinical protocols, creating a stable market for consumables through physician loyalty.

Analysis of competing companies